Matrix Science Pharma (MSP)

ABSTRACT

Objectives: The synthesis of iron oxide NP and their anticancer potential was investigated. Methods: The anticancer activities of biosynthesized iron oxide NP were evaluated using tetrazolium bromide assay, measurement of reactive oxygen species (ROS), mitochondrial membrane potential (MMP), and inhibition of tumorsphere formation. Results: In the present study, the X‑ray diffraction shows the presence of gamma phase iron oxide NP withe the type of Fe2 O3. The anticancer potential of iron oxide NP was investigated against human breast cancer cell line. The anticancer activity of biosynthesized iron oxide NP against MCF‑7 was 20.5, 30.5, 41.1, 55.3 67.5, and 75.25 at 50 µg/ml after 1, 5, 10, 15, 20, and 24 h of treatment, respectively. The results showed that Fe2 O3 NP induced ROS generation to 68.22% at the concentration of 25 µg/ml and 83.66% at 50 µg/ml as compared to 48.22 in control after 15 h of treatment. The results showed that Fe2 O3 NP treatment increased depolarization MMP to 8.52% at 25 µg/ml and 10.74% at 50 µg/ml as compared to 6.35% in untreated cells after 24 h. Thus, treatment with Fe2 O3 NPs showed significant inhibition of MCF‑7 tumorsphere formation at higher concentration. Conclusions: The biosynthesized iron oxide NP using ethyl acetate extract of C. cupreum exhibit significant anticancer activity